NCT00218543View on ClinicalTrials.gov

Atomoxetine for Treating Cocaine Abuse in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 30, 2004

Primary Completion Date

March 31, 2007

Study Completion Date

March 31, 2007

Conditions
Attention Deficit Disorder With HyperactivityCocaine-Related Disorders
Interventions
DRUG

Atomoxetine

At the start of week 7, patients will be maintained at 80 mg/day or increased to the maximal dose of 100 mg/day if less than a 50% reduction of symptoms on the ADHD Rating Scale occurs, and if the patient is tolerating the medication well.

Trial Locations (1)

10032

Research Foundation for Mental Hygiene, Inc., New York

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

New York State Psychiatric Institute

OTHER

NCT00218543 - Atomoxetine for Treating Cocaine Abuse in Adults With Attention Deficit Hyperactivity Disorder (ADHD) | Biotech Hunter | Biotech Hunter